REverse transcriptase ACTivity (REACT) assay for point-of-care measurement of established and emerging antiretrovirals for HIV treatment and prevention.

MLA

Brainerd, Cara, et al. “REverse Transcriptase ACTivity (REACT) Assay for Point-of-Care Measurement of Established and Emerging Antiretrovirals for HIV Treatment and Prevention.” Analytical and Bioanalytical Chemistry, vol. 416, no. 29, Dec. 2024, pp. 6809–18. EBSCOhost, https://doi.org/10.1007/s00216-024-05602-4.

APA

Brainerd, C., Singh, M. A., Tatka, J., Craig, C., Gilligan-Steinberg, S., Panpradist, N., Chang, M. M., Lutz, B., & Olanrewaju, A. O. (2024). REverse transcriptase ACTivity (REACT) assay for point-of-care measurement of established and emerging antiretrovirals for HIV treatment and prevention. Analytical and Bioanalytical Chemistry, 416(29), 6809–6818. https://doi.org/10.1007/s00216-024-05602-4

Chicago

Brainerd, Cara, Maya A Singh, John Tatka, Cosette Craig, Shane Gilligan-Steinberg, Nuttada Panpradist, Megan M Chang, Barry Lutz, and Ayokunle O Olanrewaju. 2024. “REverse Transcriptase ACTivity (REACT) Assay for Point-of-Care Measurement of Established and Emerging Antiretrovirals for HIV Treatment and Prevention.” Analytical and Bioanalytical Chemistry 416 (29): 6809–18. doi:10.1007/s00216-024-05602-4.